Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00977626 | Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers | PHASE1 | COMPLETED | 74 | — | — | Oct 1, 2009 | May 1, 2010 | Jan 23, 2012 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Part 1 AZD2423 or Placebo | EXPERIMENTAL | AZD2423 or Placebo Oral Solution, multiple dosing during 10-14 days |
| Part 2 - AZD2423 | EXPERIMENTAL | AZD2423 Oral solution, multiple dosing |
| Part 3 - AZD2423 | EXPERIMENTAL | AZD2423 Oral solution single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition. |
| Name | Type | Description |
|---|---|---|
| Part 1 - AZD2423 or Placebo | DRUG | AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days |
| Part 2 - AZD2423 | DRUG | AZD2423 Oral solution, multiple dosing |
| Part 3 - AZD2423 | DRUG | AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition. |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures * Healthy male and non-fertile female subjects aged ≥20 to ≤55 years inclusive and healthy male and female subjects aged ≥65 to ≤80 years inclusive with suitable veins for cannulatio...